![]() Zongfei J, Lijuan Z, Ying S, Dongmei L, Sifan W, Xiufang K, et al. An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. Wallace ZS, Khosroshahi A, Carruthers MD, Perugino CA, Choi H, Campochiaro C, et al. Diagnostic criteria for IgG4-related ophthalmic disease. Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab. ![]() Ginthör NE, Artinger K, Pollheimer MJ, Stradner MH, Eller K. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. Wu A, Andrew NH, Tsirbas A, Tan P, Gajdatsy A, Selva D. Rituximab for IgG4-related disease: a prospective, open-label trial. 2010 62:1755–62.Ĭarruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. IgG4-related disease: beyond glucocorticoids. Clinicoserological factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease. International Consensus Guidance Statement on the management and treatment of IgG4-related disease. Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. The treatment outcomes in IgG4-related orbital disease: a systematic review of the literature. 2014 43:806–17.ĭetiger SE, Karim AF, Verdijk RM, van Hagen PM, van Laar JAM, Paridaens D. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review. IgG4-related disease in the eye and ocular adnexa. It rapidly reduces ocular inflammation and serum IgG4 levels to avoid excessive corticosteroid usage and reduce potential risk of adverse events. Obinutuzumab is a safe and promising therapeutic option for IgG4-ROD. Five patients (62.5%) experienced infusion-related reactions (IRRs) during the first obinutuzumab infusion, while only one (12.5%) experienced IRRs during all subsequent eight infusions. ![]() In patients with CR, the serum IgG4 levels at baseline correlated positively with dose numbers required for CR ( r = 0.86, P < 0.05). The serum IgG4 level correlated well with IgG4-RD RI at baseline and that after each treatment ( r = 0.852, P < 0.01 r = 0.78, P < 0.001). Six patients achieved complete remission (CR) (75%) and two patients achieved partial remission (25%). The mean IgG4-RD RI scores of all patients at baseline (7.75 ± 2.92) and after treatment (2.00 ± 0.76) were highly significantly different ( P < 0.001). The number of treatment sessions was based on treatment response. They were intravenously administered 1000 mg obinutuzumab at baseline and examined for changes in physical signs, orbital structure imaging parameters, IgG4-related disease responder index (IgG4-RD RI), serological index, and adverse events during treatment. MethodsĮight IgG4-ROD patients were retrospectively enrolled. To evaluate the therapeutic efficacy and safety of obinutuzumab in remission induction for IgG4-related ophthalmic disease (IgG4-ROD) patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |